Get More Information on Biopharmaceutical market - Request Sample Report
The Biopharmaceutical Market Size was valued at USD 572.33 Billion in 2023, and is expected to reach USD 17,902.42 Billion by 2032, and grow at a CAGR of 49.60%.
The market for biopharmaceuticals is experiencing strong growth due to factors such as the rising prevalence of chronic diseases and the increasing demand for biopharmaceuticals, which can treat diseases that were previously considered untreatable. According to a report by the World Health Organization in September 2022, approximately 55 million people were living with dementia worldwide, with nearly 10 million new cases reported each year. The report also highlighted that Alzheimer's disease is the most common form of dementia, accounting for 60–70 percent of cases. The majority of individuals who develop Alzheimer's dementia are 65 years of age and older. The high incidence of disease and the growing demand for improved treatment are expected to drive the expansion of the biopharmaceutical market in the coming years.
The promising potential of biopharmaceutical products in treating previously untreatable diseases has led to the introduction of new drugs by various companies in this field. For instance, in September 2022, the Center for Biologics Evaluation and Research (CBER) granted approval to SKYSONA (elivaldogene autotemcel) from Bluebird Bio, Inc. for slowing the progression of neurologic abnormality in boys aged 4-17 years with early, active cerebral adrenoleukodystrophy (CALD). Conversely, in June 2022, CBER licensed GlaxoSmithKline's PRIORIX, a live attenuated vaccine against measles, mumps, and rubella. These product approvals are meeting the increasing demand for new medications and are expected to drive the biopharmaceutical industry during the forecast period.
Key Drivers:
The Increasing Incidence of Conditions Like Diabetes, Cancer, And Autoimmune Disorders Drives Demand for Biopharmaceutical Treatments.
Advancements In Genomics and Personalized Therapies Offer Opportunities for Tailored Treatments and Improved Patient Outcomes.
Restraints:
The Development of Biopharmaceuticals Is Expensive, Requiring Significant Investments and Often Leading to Long Timelines.
Obtaining Regulatory Approvals for New Drugs Can Be Complex and Time-Consuming, Hindering Market Entry.
Opportunity:
Expanding Access to Biopharmaceuticals in Developing Regions Presents Significant Growth Potential.
Innovations In Drug Discovery, Manufacturing, And Delivery Methods Enhance the Development and Accessibility of New Therapies.
By Type
The monoclonal antibodies held the largest market share in 2023 which is 35.2% and it is expected to continue being so in the future due to the increasing utilization of therapeutics to treat cancer. This growth is driven by the rising number of approvals, clinical trials, and increasing research expenditure. For example, Phanes Therapeutics, Inc. received Phase 1 clearance from the United States Food and Drug Administration (FDA) for PT217, a bispecific anti-Delta-like ligand 3 (DLL3)/anti-Cluster of Differentiation 47 (CD47) antibody, in October 2022. Phanes Therapeutics, Inc. developed innovative approaches to harness the immune system for patients with small cell lung cancer (SCLC) and other neuroendocrine cancers.
Additionally, the increasing number of FDA approvals and the introduction of new products for different indications will further drive the segment. For instance, the FDA approved the use of Kimmtrak in treating HLA-A-positive adult patients with unresectable or metastatic uveal melanoma, a type of cancer that begins in the eye, in January 2022. Similarly, Roche Pharma released a combinatorial kit of monoclonal antibodies and Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase in May 2022 for treating patients with breast cancer.
Based on these factors, the monoclonal antibodies segment is expected to experience significant growth during the forecast period.
Need any customization research on Biopharmaceutical Market - Enquiry Now
North America held a 40% market share in 2023. The increasing prevalence of chronic diseases unable to be treated by traditional pharmaceuticals, the presence of a large patient base across diverse indications, and the related increase in investments in R&D for this field are expected to fuel growth going forward. Moreover, the presence of established biopharmaceutical companies along with new product launches are expected to propel market growth in the region.
An increase in the number of individuals suffering from chronic diseases in the US is expected to boost market expansion. Roughly 20.1 million adults in the United States aged 20 and over have coronary heart disease, the most common type of heart disease, according to July 2022 updated data from the Centers for Disease Control and Prevention (CDC). According to the same recorded data from the CDC, every 40 seconds someone in the United States has a heart attack, and nearly 805,000 people have a first well as recurrent heart attack. Thereby, the increasing incidence of cardiovascular diseases increases the demand for new drugs for treatment, which in turn is expected to propel the growth of the biopharmaceutical market.
A growing prevalence of chronic diseases in the Canadian population and an onset of conditions associated with these disorders is also anticipated to accelerate revenue growth in the biopharmaceuticals market during the stipulated period. For example, as of July 2022, almost one out of every five Canadians (7,329,910 citizens; 18.8. %) are over the age of 65 years old according to Statistics Canada. The geriatric population is more susceptible to chronic diseases, and the growth of the elderly population is likely to increase demand for efficacious drugs for their treatment, thereby fueling the market growth.
The Players operating in the biopharmaceutical market are:
1. Pfizer
Product Portfolio: COVID-19 vaccine (Comirnaty), Prevnar (pneumococcal vaccine), Eliquis (blood thinner), Xeljanz (rheumatoid arthritis), Ibrance (breast cancer)
2. F. Hoffmann-La Roche Ltd.
Product Portfolio: Herceptin (breast cancer), Avastin (cancer), Rituxan (cancer), Ocrevus (multiple sclerosis), Tecentriq (cancer)
3. Johnson & Johnson
Product Portfolio: Janssen COVID-19 vaccine, Darzalex (multiple myeloma), Stelara (inflammatory diseases), Invega Sustenna (schizophrenia), Remicade (inflammatory diseases)
4. Novartis
Product Portfolio: Cosentyx (psoriasis), Entresto (heart failure), Zolgensma (spinal muscular atrophy), Kymriah (cancer), Tasigna (chronic myeloid leukemia)
5. Merck & Co.
Product Portfolio: Keytruda (cancer), Gardasil (HPV vaccine), Januvia (diabetes), Remicade (inflammatory diseases), Brigatinib (non-small cell lung cancer)
6. AbbVie
Product Portfolio: Humira (rheumatoid arthritis), Rinvoq (rheumatoid arthritis), Skyrizi (psoriasis), Imbruvica (blood cancer), Venclexta (blood cancer)
7. Amgen
Product Portfolio: Otezla (psoriasis), Enbrel (rheumatoid arthritis), Repatha (cholesterol), Aranesp (anemia), Neulasta (neutropenia)
8. Biogen
Product Portfolio: Tecfidera (multiple sclerosis), Spinraza (spinal muscular atrophy), Aduhelm (Alzheimer's disease), Ocrevus (multiple sclerosis), Hemera (multiple sclerosis)
9. Eli Lilly and Company
Product Portfolio: Trulicity (diabetes), Humalog (insulin), Verzenio (breast cancer), Taltz (psoriasis), Jardiance (diabetes)
10. AstraZeneca
Product Portfolio: Tagrisso (lung cancer), Farxiga (diabetes), Lynparza (ovarian cancer), Calquence (chronic lymphocytic leukemia), Imfinzi (lung cancer)
11. Bayer
Product Portfolio: Xarelto (blood thinner), Eylea (age-related macular degeneration), Xigduo XR (diabetes), Adempas (pulmonary arterial hypertension), Stivarga (colorectal cancer)
12. Sanofi
Product Portfolio: Lantus (insulin), Adlyxin (diabetes), Dupixent (atopic dermatitis), Lixiana (blood thinner), Cabenuva (HIV)
13. Bristol Myers Squibb
Product Portfolio: Revlimid (multiple myeloma), Eliquis (blood thinner), Opdivo (cancer), Yervoy (cancer), Pomalyst (multiple myeloma)
14. Takeda Pharmaceutical Company Limited
Product Portfolio: Entyvio (inflammatory bowel disease), Velcade (multiple myeloma), Vyvanse (ADHD), Livsty (hepatitis C), Brilinta (platelet inhibitor)
15. Gilead Sciences
Product Portfolio: Biktarvy (HIV), Descovy (HIV), Truvada (HIV), Genvoya (HIV), Epclusa (hepatitis C)
16. Vertex Pharmaceuticals
Product Portfolio: Kalydeco (cystic fibrosis), Orkambi (cystic fibrosis), Symdeko (cystic fibrosis), Trikafta (cystic fibrosis)
17. GlaxoSmithKline
Product Portfolio: Shingrix (shingles vaccine), Trelegy Ellipta (COPD), Nucala (asthma), Advair (asthma), Benlysta (lupus)
18. AbbVie
Product Portfolio: Humira (rheumatoid arthritis), Rinvoq (rheumatoid arthritis), Skyrizi (psoriasis), Imbruvica (blood cancer), Venclexta (blood cancer)
19. Moderna
Product Portfolio: COVID-19 vaccine, mRNA-based cancer vaccines
20. Regeneron Pharmaceuticals
Product Portfolio: Dupixent (atopic dermatitis), Eylea (age-related macular degeneration), Libtayo (cancer), Dupixent (asthma)
21. Novo Nordisk
Product Portfolio: NovoRapid (insulin), Levemir (insulin), Ozempic (GLP-1 receptor agonist), Rybelsus (GLP-1 receptor agonist), Victoza (GLP-1 receptor agonist)
In July 2023, Pfizer invested USD 25 million in Caribou Biosciences to advance an immune-evasive, allogeneic CAR-T cell therapy, CB-011. The cell therapy is being assessed in a Phase I CaMMouflage trial for people with relapsed or refractory multiple myeloma.
In April 2023, InflaRx N.V. was also granted an Emergency Use Authorization by the United States Food and Drug Administration for its first-in-class monoclonal anti-human complement factor C5a antibody Gohibic (vilobelimab) to be used to treat COVID-19 in hospitalized adults when administered within 48 hours of initiation of mechanical ventilation or extracorporeal membrane oxygenation.
| Report Attributes | Details |
| Market Size in 2023 | US$ 572.33 Billion |
| Market Size by 2032 | US$ 17,902.42 Billion |
| CAGR | CAGR of 49.60% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type(Monoclonal antibody, Interferon, Insulin, Growth and coagulation factor, Erythropoietin, Vaccine, Hormone, Others) • By Application(Oncology, Blood disorder, Metabolic disease, Infectious disease, Cardiovascular disease, Neurological disease, Immunology, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Pfizer, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis, Merck & Co., AbbVie, Amgen, Biogen, Eli Lilly and Company, AstraZeneca, Bayer, Sanofi, Bristol Myers quibb, Takeda Pharmaceutical Company Limited, Gilead Sciences, Vertex Pharmaceuticals, GlaxoSmithKline, AbbVie, Moderna, Regeneron Pharmaceuticals, Novo Nordisk, Others |
| Key Drivers | • The Increasing Incidence of Conditions Like Diabetes, Cancer, And Autoimmune Disorders Drives Demand for Biopharmaceutical Treatments. • Advancements In Genomics and Personalized Therapies Offer Opportunities for Tailored Treatments and Improved Patient Outcomes. |
| Market Opportunities | • Expanding Access to Biopharmaceuticals in Developing Regions Presents Significant Growth Potential. • Innovations In Drug Discovery, Manufacturing, And Delivery Methods Enhance the Development and Accessibility of New Therapies. |
Ans: The Biopharmaceutical Market will be valued at USD 17,902.42 Billion in 2032.
Ans: The Biopharmaceutical Market was valued at USD 572.33 Billion in 2023.
Ans: The expected CAGR of the Global Biopharmaceutical Market during the forecast period is 49.60%
Ans: Monoclonal Antibody held the largest Biopharmaceutical Market share in 2023.
Ans: The North America led Biopharmaceutical Market.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Technological Advancements
5.2 Reimbursement Scenario
5.3 Regulatory Impact: Effects of regulations on production and usage.
5.4 Environmental Metrics Analysis by Region
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Biopharmaceutical Market Segmentation by Type
7.1 Chapter Overview
7.2 Monoclonal Antibody
7.2.1 Monoclonal Antibody Market Trends Analysis (2020-2032)
7.2.2 Monoclonal Antibody Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Interferon
7.3.1 Interferon Market Trends Analysis (2020-2032)
7.3.2 Interferon Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Insulin
7.4.1 Insulin Market Trends Analysis (2020-2032)
7.4.2 Insulin Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Growth and Coagulation Factor
7.5.1 Growth and Coagulation Factor Market Trends Analysis (2020-2032)
7.5.2 Growth and Coagulation Factor Disorders Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Erythropoietin
7.6.1 Erythropoietin Market Trends Analysis (2020-2032)
7.6.2 Erythropoietin Market Size Estimates and Forecasts to 2032 (USD Billion)
7.7 Vaccine
7.7.1 Vaccine Market Trends Analysis (2020-2032)
7.7.2 Vaccine Market Size Estimates and Forecasts to 2032 (USD Billion)
7.8 Hormone
7.8.1 Hormone Market Trends Analysis (2020-2032)
7.8.2 Hormone Market Size Estimates and Forecasts to 2032 (USD Billion)
7.9 Others
7.9.1 Vaccine Market Trends Analysis (2020-2032)
7.9.2 Vaccine Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Biopharmaceutical Market Segmentation, by Application
8.1 Chapter Overview
8.2 Oncology
8.2.1 Oncology Market Trends Analysis (2020-2032)
8.2.2 Oncology Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Blood Disorder
8.3.1 Blood Disorder Market Trends Analysis (2020-2032)
8.3.2 Blood Disorder Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Metabolic Disease
8.3.1 Metabolic Disease Market Trends Analysis (2020-2032)
8.3.2 Metabolic Disease Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Infectious Disease
8.5.1 Infectious Disease Market Trends Analysis (2020-2032)
8.5.2 Infectious Disease Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Cardiovascular Disease
8.6.1 Cardiovascular Disease Market Trends Analysis (2020-2032)
8.6.2 Cardiovascular Disease Market Size Estimates and Forecasts to 2032 (USD Billion)
8.7 Neurological Disease
8.7.1 Neurological Disease Market Trends Analysis (2020-2032)
8.7.2 Neurological Disease Market Size Estimates and Forecasts to 2032 (USD Billion)
8.8 Immunology
8.8.1 Immunology Market Trends Analysis (2020-2032)
8.8.2 Immunology Market Size Estimates and Forecasts to 2032 (USD Billion)
8.9 Others
8.9.1 Others Market Trends Analysis (2020-2032)
8.9.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Biopharmaceutical Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.2.4 North America Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.2.6 USA
9.2.6.1 USA Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.2.6.2 USA Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.2.7 Canada
9.2.7.1 Canada Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.2.7.2 Canada Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.2.8 Mexico
9.2.8.1 Mexico Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.2.8.2 Mexico Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Biopharmaceutical Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.6 Poland
9.3.1.6.1 Poland Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.1.6.2 Poland Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.7 Romania
9.3.1.7.1 Romania Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.1.7.2 Romania Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.8 Hungary
9.3.1.8.1 Hungary Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.1.8.2 Hungary Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.9 Turkey
9.3.1.9.1 Turkey Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.1.9.2 Turkey Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Biopharmaceutical Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.4 Western Europe Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.6 Germany
9.3.2.6.1 Germany Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.6.2 Germany Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.7 France
9.3.2.7.1 France Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.7.2 France Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.8 UK
9.3.2.8.1 UK Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.8.2 UK Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.9 Italy
9.3.2.9.1 Italy Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.9.2 Italy Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.9.2 Spain Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.12 Switzerland
9.3.2.12.1 Switzerland Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.12.2 Switzerland Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.13 Austria
9.3.2.13.1 Austria Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.13.2 Austria Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.14 Rest of Western Europe
9.3.2.14.1 Rest of Western Europe Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.14.2 Rest of Western Europe Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Biopharmaceutical Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.4 Asia Pacific Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.6 China
9.4.6.1 China Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.6.2 China Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.7 India
9.4.7.1 India Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.7.2 India Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.8 Japan
9.4.8.1 Japan Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.8.2 Japan Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.9 South Korea
9.4.9.1 South Korea Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.9.2 South Korea Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.9 Vietnam
9.4.9.1 Vietnam Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.9.2 Vietnam Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.10 Singapore
9.4.10.1 Singapore Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.10.2 Singapore Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.12 Australia
9.4.12.1 Australia Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.12.2 Australia Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.13 Rest of Asia Pacific
9.4.13.1 Rest of Asia Pacific Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.13.2 Rest of Asia Pacific Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Biopharmaceutical Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.1.4 Middle East Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.6 UAE
9.5.1.6.1 UAE Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.1.6.2 UAE Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.7 Egypt
9.5.1.7.1 Egypt Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.1.7.2 Egypt Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.8 Saudi Arabia
9.5.1.8.1 Saudi Arabia Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.1.8.2 Saudi Arabia Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.9 Qatar
9.5.1.9.1 Qatar Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.1.9.2 Qatar Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Biopharmaceutical Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.2.4 Africa Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.2.6 South Africa
9.5.2.6.1 South Africa Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.2.6.2 South Africa Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.2.7 Nigeria
9.5.2.7.1 Nigeria Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.2.7.2 Nigeria Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.2.8 Rest of Africa
9.5.2.8.1 Rest of Africa Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.2.8.2 Rest of Africa Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Biopharmaceutical Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.6.4 Latin America Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.6 Brazil
9.6.6.1 Brazil Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.6.6.2 Brazil Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.7 Argentina
9.6.7.1 Argentina Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.6.7.2 Argentina Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.8 Colombia
9.6.8.1 Colombia Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.6.8.2 Colombia Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.9 Rest of Latin America
9.6.9.1 Rest of Latin America Biopharmaceutical Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.6.9.2 Rest of Latin America Biopharmaceutical Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10. Company Profiles
10.1 F. Hoffmann-La Roche Ltd.
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
10.1.4 SWOT Analysis
10.2 Pfizer Inc.
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 Novo Nordisk A/S
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Johnson & Johnson
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Sanofi
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 Abbott Laboratories
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Amgen Inc.
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Biogen Inc.
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Merck & Co., Inc.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 Eli Lilly and Company
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Products/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Type
Monoclonal antibody
Interferon
Insulin
Growth and coagulation factor
Erythropoietin
Vaccine
Hormone
Others
By Application
Oncology
Blood disorder
Metabolic disease
Infectious disease
Cardiovascular disease
Neurological disease
Immunology
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Genotyping Market Size was valued at USD 17.24 billion in 2023, and is expected to reach USD 58.80 billion by 2032, and grow at a CAGR of 14.6% over the forecast period 2024-2032.
The Augmented and Virtual Reality Contact Lenses Market size was valued at USD 21.60 Million in 2023 and is expected to grow to USD 71.80 Million by 2031 and grow at a CAGR of 16.2 % over the forecast period of 2024-2031.
The Single-cell Omics Market size was estimated at USD 1.61 billion in 2023 and is expected to reach USD 6.21 billion by 2032 with a growing CAGR of 16.2% during the forecast period of 2024-2032.
The Morphine Market was valued at USD 20.03 billion in 2023 and is expected to reach USD 32.81 billion by 2032 and grow at a CAGR of 5.66% from 2024 to 2032.
The Medical Swabs Market was valued at USD 3.15 billion in 2023 and is expected to reach USD 5.69 billion by 2032, growing at a CAGR of 6.8% by 2024-2032.
The Bovine Mastitis Market size was USD 0.60 Billion in 2023 and is expected to Reach USD 0.98 Billion by 2031 and grow at a CAGR of 6.4% over the forecast period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
